# Study to Evaluate the Safety of MEDI-534 Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) in Healthy Children

> **NCT00345670** · PHASE1 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 120 (—)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** MEDI-534
- **BIOLOGICAL:** MEDI-534
- **BIOLOGICAL:** MEDI-534

## Key facts

- **NCT ID:** NCT00345670
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** —
- **Final completion:** 2007-05
- **Target enrollment:** 120 (—)
- **Last updated:** 2008-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00345670

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00345670, "Study to Evaluate the Safety of MEDI-534 Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) in Healthy Children". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00345670. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*